Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0DV3O
|
||||
| Former ID |
DAP001074
|
||||
| Drug Name |
Epinastine
|
||||
| Synonyms |
Epinastina; Epinastinum; Purivist; Epinastina [Spanish]; Epinastine [INN]; Epinastinum [Latin]; WAL 80; WAL 801; WAL 801CL; Elestat (TN); Epinastine (INN); Purivist (TN); Relestat (TN); WAL-80 Cl; (+-)-Epinastine; 3-Amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepine; 3-amino-9,13b-dihydro-1H-benz(c,f)imidazo(1,5a)azepine; 9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-amine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Allergic conjunctivitis [ICD9: 204.0, 372.0, 372.14, 995.3; ICD10:C91.0, H10, H10.45, T78.4] | Approved | [1], [2] | ||
| Therapeutic Class |
Antihistamines
|
||||
| Company |
Allergan Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H15N3
|
||||
| InChI |
InChI=1S/C16H15N3/c17-16-18-10-15-13-7-3-1-5-11(13)9-12-6-2-4-8-14(12)19(15)16/h1-8,15H,9-10H2,(H2,17,18)
|
||||
| InChIKey |
WHWZLSFABNNENI-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 80012-43-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
5173366, 8152057, 14847686, 29217549, 29222382, 46509056, 50065222, 50111706, 56464356, 57321677, 75376315, 81041126, 85209437, 85286058, 90340676, 92714612, 96024596, 103305708, 104022599, 104302939, 118313772, 125357916, 126629485, 126655288, 126684289, 129584096, 134338331, 135026263, 136912969, 137101854, 142087407, 152034622, 152253736, 160964094, 162176284, 164814672, 178103751, 179148544, 196106483, 206246277, 210279785, 210282108, 221672861, 223381334, 223435039, 223681981, 224278905, 226408729, 251912269, 251916574
|
||||
| ChEBI ID |
ChEBI:51037
|
||||
| SuperDrug ATC ID |
R06AX24; S01GX10
|
||||
| SuperDrug CAS ID |
cas=080012437
|
||||
| Target and Pathway | |||||
| Target(s) | Histamine H1 receptor | Target Info | Antagonist | [3] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | Histamine H1 receptor mediated signaling pathway | ||||
| Reactome | Histamine receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| IL-4 Signaling Pathway | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7176). | ||||
| REF 3 | Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cells in vitro and in vivo. Mediators Inflamm. 2009;2009:738038. Epub 2009 Apr 9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.